Evidence map›Paper›PMID 38798554›Full record

ArticlebioRxiv : the preprint server for biology2024

Immunotherapy-related cognitive impairment after CAR T cell therapy in mice.

Anna C Geraghty, Lehi Acosta-Alvarez, Maria Rotiroti, Selena Dutton, Michael R O'Dea, Pamelyn J Woo, Haojun Xu, Kiarash Shamardani, Rebecca Mancusi, Lijun Ni and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Anna C GeraghtyDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA USA 94305.ORCID 0000-0001-5914-1412
Lehi Acosta-AlvarezDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA USA 94305.
Maria RotirotiDepartment of Pediatrics, Stanford School of Medicine, Stanford, CA USA 94305.
Selena DuttonDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA USA 94305.
Michael R O'DeaNeuroscience Institute, NYU Grossman School of Medicine, New York, NY USA 10016.
Pamelyn J WooDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA USA 94305.
Haojun XuDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA USA 94305.
Kiarash ShamardaniDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA USA 94305.
Rebecca MancusiDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA USA 94305.
Lijun NiDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA USA 94305.
Sara B MulinyaweDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA USA 94305.
Won Ju KimDepartment of Pediatrics, Stanford School of Medicine, Stanford, CA USA 94305.
Shane A LiddelowNeuroscience Institute, NYU Grossman School of Medicine, New York, NY USA 10016.ORCID 0000-0002-0840-1437
Robbie G MajznerDepartment of Pediatrics, Stanford School of Medicine, Stanford, CA USA 94305.ORCID 0000-0001-6969-8011
Michelle MonjeDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA USA 94305.ORCID 0000-0002-3547-237X

Funding

Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI KEITH LLOYD LIGON · 2013 to 2026
$33.5M
Targeting the neuronal microenvironment in glioblastomaU19CA264504 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Michelle Monje-Deisseroth · 2021 to 2026
$6.4M
Glioma Circuitry: Bridging Systems Neuroscience and CancerDP1NS111132 · NINDS · STANFORD UNIVERSITY · PI MONJE-DEISSEROTH, MICHELLE · 2018 to 2022
$5.7M
Neuronal Regulation of Low-Grade GliomagenesisR01CA258384 · NCI · STANFORD UNIVERSITY · PI David H Gutmann, Michelle Monje-Deisseroth · 2022 to 2026
$3.1M
Neurotoxicity of Reactive Astrocyte-secreted Lipids in Neurodegenerative DiseaseR01EY033353 · NEI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Shane Liddelow · 2022 to 2026
$2.5M
Neuronal activity-regulated mechanisms of glioma growthR01NS092597 · NINDS · STANFORD UNIVERSITY · PI MONJE-DEISSEROTH, MICHELLE · 2016 to 2021
$2.1M
NCI NIH HHS P50 CA165962NCI NIH HHS R01 CA258384NCI NIH HHS U19 CA264504NEI NIH HHS R01 EY033353NINDS NIH HHS DP1 NS111132NINDS NIH HHS R01 NS092597
6 · The paper itself

Abstract

Persistent central nervous system (CNS) immune dysregulation and consequent dysfunction of multiple neural cell types is central to the neurobiological underpinnings of a cognitive impairment syndrome that can occur following traditional cancer therapies or certain infections. Immunotherapies have revolutionized cancer care for many tumor types, but the potential long-term cognitive sequelae are incompletely understood. Here, we demonstrate in mouse models that chimeric antigen receptor (CAR) T cell therapy for both CNS and non-CNS cancers can impair cognitive function and induce a persistent CNS immune response characterized by white matter microglial reactivity and elevated cerebrospinal fluid (CSF) cytokines and chemokines. Consequently, oligodendroglial homeostasis and hippocampal neurogenesis are disrupted. Microglial depletion rescues oligodendroglial deficits and cognitive performance in a behavioral test of attention and short-term memory function. Taken together, these findings illustrate similar mechanisms underlying immunotherapy-related cognitive impairment (IRCI) and cognitive impairment following traditional cancer therapies and other immune challenges.

Identifiers

PMID38798554
PMCPMC11118392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.